Company

We are designers and suppliers of generic and customised inhaler device platforms. Our devices include multidose dry powder inhalers, capsule dry powder inhalers, soft mist inhalers and devices tailored to cannabinoid delivery to the lungs. Our customers take our devices and combine them with their drug formulation to make final dosage forms that are supplied to users and patients. We create, develop and supply device platforms for evaluation through to commercial supply. Merxin Ltd device platforms save customers money and time to develop, file and market inhaled dosage forms. We take problems away from our customer. We do it so they don’t have to. We are a trusted partner. We are part of the solution.

Our DNA is in the pharma industry: we deliver quality, reliability and efficacy. The Merxin Ltd team has a thorough understanding and long history of medical device and pharmaceutical product development. Our reputation is built on excellence and audacity.

Merxin Ltd is active in the fields of pharmaceuticals and inhaled cannabinoids therapies (iCTx). We make devices that treat lung diseases such as asthma and cannabis therapies reliable.

Quality is in our veins. Merxin Ltd has been assessed and certified as meeting the requirements of ISO 13485:2016 for the Design, Development and Supply of inhalers. We believe in Quality, we deliver Reliability.

Established in the UK in 2015 and based in King’s Lynn, with manufacturing capacity across the globe and an international client base, we are now adding more products to our portfolio and expanding rapidly, which is why we need you. In March we won the King’s Lynn Mayor’s Business of the Year Award.

Team Vision History Awards & Accreditations Careers

Graham

Chief Technology Officer

Chief Technology Officer and founder of Merxin Ltd. Graham is a chartered engineer and medical device expert with an accomplished track record delivering technology and global projects across R&D and commercial industrialisation. Previous lives include Head of Hardware Development at 3M Health Care, Device Engineering Group Manager at Novartis and Programme Manager at Bespak leading the construction and setting up of the UK's largest clean room manufacturing facility for the Mylan generic Advair DPI platform. Building and leading effective teams and delivering exciting projects proves so much fun that his leisure time is filled with a never-ending series of house renovation projects.

Philippe

Chief Business Officer

Chief Business officer and founder of Merxin Ltd, Philippe is a formulation expert with a global reputation. Philippe is a fellow of the Woolcock Respiratory Institute at Sydney University, and formerly Executive Director at Actavis Pharma, where he set up their generic inhalation pipeline. He has an enviable track record in developing pMDI, DPI, Nebules, Nasal and soft mist inhalers in both generic and originator companies. Philippe recently founded Anthocan Ltd, a company dedicated to inhaled cannabinoid therapies. Philippe founded Merxin Ltd with Graham, where he makes sure Merxin Ltd provides devices the markets seek and that Merxin Ltd is a sound and successful business where creativity and fun go hand in hand.

Vision - Generic & Customised

Merxin Ltd is a designer, developer and supplier of generic and customised drug delivery and medical device platforms.

Merxin Ltd supplies customers with devices ready to be filled with proprietary formulations. Merxin Ltd creates, develops and supplies device platforms for evaluation through to commercial supply.

Merxin Ltd device platforms save its customers money and time to develop, file and market inhaled dosage forms. We take problems away from our customer. We do it so they don’t have to. We are a trusted partner. We are part of the solution.

Quality is in our veins. Merxin Ltd has been assessed and certified as meeting the requirements of ISO 13485:2016 for the Design, Development and Supply of inhalers.

Merxin Ltd is active in the fields of pharmaceuticals, inhaled cannabinoids therapies (iCTx) and reduced risk nicotine inhalers (RiNih).

The benefits of working with Merxin Ltd are:

Ready to use devices with no lengthy nor costly device designing
Reduced project risk
Fast access to standardised device platforms
Recognised and popular technologies
Devices customized to client’s requirements
Possibility for telehealth adaption (DTx, digital therapeutics)

Reduce Cost, Reduce Risk, Increase Success

History

Merxin Ltd's is ISO13485:2016 certified by BSI

2020

MRX003 first commercial manufacturing line ready

2020

MRX001 Approved by the FDA

2019

Merxin Ltd wins King’s Lynn and West Norfolk Mayor Business of the year Award

2019

Perlen and Merxin Ltd partner to develop BLISTair for Cannabis

2019

MRX001 achieves in vitro bioequivalence against fluticasone+salmeterol DPI reference product

2018

Merxin Ltd is the recipient of European Union R&D Funds

2018

MRX003 gets CE marked

2017

Launch of MRX004 soft mist inhaler as a generic device for tiotropium/olodaterol soft mist inhaler

2018

Merxin Ltd gets ISO13485:2016 compliance

2017

Merxin Ltd moves to King’s Lynn offices

2017

Launch of MRX003 (tiotropium capsule DPI)

2017

Launch of MRX001 (multidose blister dry powder inhaler)

2016

Launch of MRX002, clear pMDI canister

2016

Founding of Merxin Ltd

2015

< Forward

Back >

Awards & Accreditations

ISO 13485:2016

In December 2017, Merxin Ltd was assessed and certified as meeting the requirements of ISO 13485:2016 for the Design, Development and Supply of inhalers.

Our ISO 13485:2016 accreditation recognises the quality management systems that Merxin Ltd have in place, reflected in the quality of standards across our products and services. Merxin Ltd is qualified to supply regulated markets such as the EU, Japan, Canada, Australia and US.

FDA substitutability of MRX003

In February 2017, MRX003, our capsule DPI inhaler was given the nod by the FDA as a suitable generic device with which to file a 505j ANDA of Spiriva HandiHaler (tiotropium).

The origins of Merxin Ltd are in the generic world, we design devices that accelerate generic filing: performance and handling are matched to the originator product while avoiding existing I.P. Merxin Ltd excels at this. We take this expertise to make device platforms for new molecules and combinations.

CE marking of MRX003

In December 2017, a version of our Capsule inhaler MRX003 was cleared for CE marking and use in clinical trials.

We do not simply design devices, we make them compliant with the necessary device regulations in EU and US, ready for human use, clinical trials and commercial launch. Pharmaceutical quality is in our DNA.

EU Regional Development Fund Grant

In December 2018, Merxin Ltd was awarded a grant from the New Anglia Business Growth Programme - Small Grant Scheme, part funded by the European Regional Development Fund.

The funds were used to accelerate Merxin Ltd R&D plans and enabled us to invest in new equipment, Malvern Spraytec and Mitutoyo Metrology, to increase our services to our clients.

We are committed to exceed our customers’ expectation and work and run with them towards filing, approval and launch of their products. The commercial success of our clients is the measure of our success.

Business of the Year awards – 2019

In March 2019, Merxin Ltd was named as West Norfolk’s top company.

We were awarded the Mayor’s Business of the Year Award 2019 by King’s Lynn and West Norfolk council.

The award recognises ambition, drive, innovation and determination demonstrated by the businesses of West Norfolk and their contribution to the King’s Lynn and West Norfolk economy.

As the leading medical device company in King’s Lynn we want to help grow a high-tech ecosystem reliant on local talent and accessibility.

We are proud to be recognised for our ground-breaking innovation and our ambitious vision for our future in King’s Lynn.

Careers

Merxin Ltd is always looking for new talent and will be pleased to hear from future team members wanting to join us.

We use a transparent and engaging recruitment process that opens a creative dialogue with candidates. We like candidates, we appreciate the effort they go to when applying for a position at Merxin Ltd. We treat them fairly and openly. We communicate with them whatever the outcome.

That means we do not use over rated recruitment databases and we do not engage copycat bland self-styled recruitment executives. Our future employees deserve more than being treated as statistics.

We advertise our vacancies on LinkedIn, Indeed and other major job search websites.

If you are a recruitment agency trying to sell us yet another CV database, have a cup of tea, treat yourself, don’t waste your time.